The US eosinophilic esophagitis (EoE) market, valued at $156.7 million in 2020, is projected to grow at a compound annual growth rate (CAGR) of 25.7%, to reach $1.5 billion by 2030.
However, despite this impressive growth rate, low diagnosis rates caused by limited disease awareness will continue to keep the diagnosis cases at a low rate, says data and analytics company GlobalData.
EoE is defined as a chronic, immune-mediated, atopic inflammatory condition of the esophagus, recognized over the past two decades. In EoE, eosinophils infiltrate the esophagus, contributing to tissue damage and chronic inflammation. The condition is diagnosed by histologic analysis of ≥15 eosinophils per high power field (eos/hpf) in one or more esophageal biopsy specimens and exclusion of pathologic gastrointestinal reflux disease (GERD). EoE symptoms are similar to GERD, which is why the two conditions were thought to be the same for so long. The key to diagnosing EoE is that patients with EoE do not improve with GERD medications.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze